Therapeutic Benefit of Galectin-1: Beyond Membrane Repair, a Multifaceted Approach to LGMD2B

• Published in: Cells (Basel, Switzerland) Vol. 10; no. 11; p. 3210
• Main Authors: Vallecillo-Zúniga, Mary L, Poulson, Peter Daniel, Luddington, Jacob S, Arnold, Christian J, Rathgeber, Matthew, Kartchner, Braden C, Hayes, Spencer, Gill, Hailie, Valdoz, Jonard C, Spallino, Jonathan L, Garfield, Seth, Dodson, Ethan L, Arthur, Connie M, Stowell, Sean R, Van Ry, Pam M
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 17.11.2021; MDPI
• Subjects: Animal models; Animals; Biomarkers - metabolism; Cytokines; Cytokines - metabolism; Dysferlin - deficiency; Dysferlin - metabolism; Galectin 1 - therapeutic use; Galectin-1; Humans; Inflammation; Inflammation - pathology; Lasers; LGMD2B; Male; membrane repair; Membranes; Mice; Muscle Fibers, Skeletal - metabolism; Muscle strength; Muscular Dystrophies, Limb-Girdle - pathology; Muscular dystrophy; Musculoskeletal system; NF-kappa B - metabolism; NF-ĸB; NF-κB protein; Patients; Protein Multimerization; Proteins; Recombinant Proteins - therapeutic use; Signal Transduction; United States > US; Chicago Illinois; muscular dystrophy; NF-ĸB; inflammation; Galectin-1; cytokines; LGMD2B; membrane repair
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells10113210

Two of the main pathologies characterizing dysferlinopathies are disrupted muscle membrane repair and chronic inflammation, which lead to symptoms of muscle weakness and wasting. Here, we used recombinant human Galectin-1 (rHsGal-1) as a therapeutic for LGMD2B mouse and human models. Various redox and multimerization states of Gal-1 show that rHsGal-1 is the most effective form in both increasing muscle repair and decreasing inflammation, due to its monomer-dimer equilibrium. Dose-response testing shows an effective 25-fold safety profile between 0.54 and 13.5 mg/kg rHsGal-1 in Bla/J mice. Mice treated weekly with rHsGal-1 showed downregulation of canonical NF-κB inflammation markers, decreased muscle fat deposition, upregulated anti-inflammatory cytokines, increased membrane repair, and increased functional movement compared to non-treated mice. Gal-1 treatment also resulted in a positive self-upregulation loop of increased endogenous Gal-1 expression independent of NF-κB activation. A similar reduction in disease pathologies in patient-derived human cells demonstrates the therapeutic potential of Gal-1 in LGMD2B patients.